Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924244 | 0.84 | CYP46A1 (0.39) | PIK3CDHCRTR2HCRTR1TP53PRCP | |
| SCHEMBL2930955 | 0.83 | HCRTR2 (0.38) | PIK3CDHCRTR2HCRTR1TP53PRCP | |
| SCHEMBL8205452 | 0.83 | MGLL (0.40) | MGLLPIK3CDHCRTR2HCRTR1TP53 | |
| SCHEMBL13538909 | 0.83 | HCRTR1 (0.41) | HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL2926433 | 0.82 | MGLL (0.38) | MGLLPIK3CDHCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL2931914 | 0.82 | HCRTR2 (0.39) | PIK3CDHCRTR2HCRTR1 | |
| SCHEMBL2925493 | 0.80 | HCRTR2 (0.37) | PIK3CDHCRTR2HCRTR1 | |
| SCHEMBL2930744 | 0.80 | HCRTR2 (0.37) | PIK3CDHCRTR2HCRTR1PRCP | |
| SCHEMBL13176494 | 0.80 | HCRTR1 (0.39) | MGLLPIK3CDHCRTR2HCRTR1 | |
| SCHEMBL2930074 | 0.79 | SLC6A7 (0.35) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | MGLL 4396/4885PIK3CD 1972/4885HCRTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.